Skip to main content

Dr. Asha L. Bailey, DO

Nephrology (Kidney) (Nephrology Physician)

  • Medicare participating

At a glance

Years since graduation
19
In the NPI registry since
2007
Medicare patients seen, 2024
497

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Medical school: Philadelphia College of Osteopathic Medicine
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Nephrology Physician primary
    SC license 1541 · MS license 34462 · TN license 6022

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Nephrology (Kidney) per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
497
Services billed
3,443
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Total protein level, urine290177
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes289139
Creatinine level to test for kidney function or muscle injury289176
Kidney function blood test panel278167
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count276166
Manual urinalysis test with examination using microscope, automated260159
Insertion of needle into vein for collection of blood sample251144
Dialysis services, 4 or more physician visits per month (20 years or older)25053
Parathormone (parathyroid hormone) level238152
Established patient office or other outpatient visit, 30-39 minutes214151

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 44 payments worth $902 in total to this clinician.

By company
Novartis Pharmaceuticals Corporation$346
Calliditas Therapeutics US Inc.$142
AstraZeneca Pharmaceuticals LP$93.36
Amgen Inc.$88.58
Novo Nordisk Inc$46.56
Fresenius USA Marketing, Inc.$38.45
Scpharmaceuticals Inc.$37.15
Ardelyx, Inc.$26.97
By type
Food and Beverage$902

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in South Carolina →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $254,998 in research payments for these studies, mostly to the institutions running them.

  • Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
    Csl Behring · Recruiting · NCT05485961
  • A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
    AstraZeneca Pharmaceuticals LP
  • A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
    AstraZeneca Pharmaceuticals LP
  • A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
    Novartis Pharmaceuticals Corporation
  • Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APP…
    AstraZeneca UK Limited

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Columbia

Sources

NPI registry (CMS NPPES, November 2026; record last updated December 15, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1619156957. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.